Literature DB >> 2937801

Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer.

A Bélanger, M Brochu, J Cliche.   

Abstract

The levels of plasma dehydroepiandrosterone (DHEA), androst-5-ene-3 beta,17 beta-diol (delta 5-diol), testosterone (T), dihydrostestosterone (DHT), androstane-3 alpha,17 beta-diol (3 alpha-diol), androsterone (ADT), and the related glucuronide (G) derivatives were determined in intact and castrated men with prostatic cancer. The plasma concentrations of DHEA and DHEA-G were not significantly different in intact and castrated men while delta 5-diol as well as delta 5-diol-G were 50% lowered in castrated men. As expected, T and DHT concentrations were markedly lower in castrated men. These low plasma levels of T and DHT were accompanied by a decrease of 3 alpha-diol, ADT, T-G, 3 alpha-diol-G, and ADT-G levels. There was, in unoperated men, a positive correlation between the levels of DHEA and ADT-G as well as DHEA and DHEA-G, while T values were highly correlated with ADT-G and 3 alpha-diol-G levels. Furthermore, a significant relationship was found between DHEA and ADT-G as well as 3 alpha-diol-G in castrated men. Our data clearly demonstrate that ADT-G and 3 alpha-diol-G levels are more affected by castration than are the corresponding unconjugated steroids and suggest that these steroid glucuronides should be good markers of androgen metabolism. Moreover, the significant relationship between DHEA, ADT-G, and 3 alpha-diol-G in castrated men also suggests that approximately 30% of C-19 steroids from the adrenals are converted to T and DHT, which are further transformed into steroid glucuronides.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937801     DOI: 10.1210/jcem-62-5-812

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  DHEA as physiological replacement therapy at menopause.

Authors:  F Labrie
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

Review 2.  Endocrine and adrenergic pharmacological intervention in diseases of the prostate.

Authors:  A Rane
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

3.  3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.

Authors:  Hiroshi Miyamoto; Padma Marwah; Ashok Marwah; Henry Lardy; Chawnshang Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

4.  Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.

Authors:  H C Chang; H Miyamoto; P Marwah; H Lardy; S Yeh; K E Huang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 5.  Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.

Authors:  F Labrie; A Dupont; A Bélanger; L Cusan; M Giguère; Y Lacourcière; I Luthy; D Bégin; C Labrie; J Simard
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

6.  Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.

Authors:  Tianzhu Zang; Daniel Tamae; Clementina Mesaros; Qingqing Wang; Meng Huang; Ian A Blair; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2016-08-12       Impact factor: 4.292

Review 7.  DHEA and the skeleton (through the ages).

Authors:  C M Gordon; J Glowacki; M S LeBoff
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

8.  Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.

Authors:  Gang Wu; Shengsong Huang; Kent L Nastiuk; Jinliang Li; Jun Gu; Ming Wu; Qimin Zhang; Hanqing Lin; Denglong Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

Review 9.  Androgen receptor gene and hormonal therapy failure of prostate cancer.

Authors:  P Koivisto; M Kolmer; T Visakorpi; O P Kallioniemi
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

10.  The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer.

Authors:  S Balzano; M Cappa; R Migliari; R M Scarpa; E Danielli; G Campus; C Pintus; V Sica; E Usai; E Martino
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.